Key result
RAGE biomarkers and polymorphisms may predict vascular disease risk and serve as therapeutic targets.
Answers are grounded in this paper and cite their sources.
Demonstrates that circulating RAGE levels and AGER gene variants track vascular disease severity, highlighting their potential as predictive biomarkers and therapeutic targets.
RAGE [receptor for AGEs (advanced glycation end-products)] plays an important role in the development and progression of vascular disease. Studies in cultured cells and small animal models of disease have clearly demonstrated that RAGE is central to the pathogenesis of vascular disease of the macro- and micro-vessels in both the diabetic and non-diabetic state. Emerging results from human clinical studies have revealed that levels of circulating soluble RAGE in the plasma may reflect the presence and/or extent of vascular disease state. Additionally, genetic variants of the RAGE gene (AGER in HUGO nomenclature) have been associated with vascular disease risk. Combining RAGE circulating protein levels and the presence of particular RAGE polymorphisms may be a useful clinical tool for the prediction of individuals at risk for vascular disease. Therapeutic intervention targeted at the RAGE gene may therefore be a useful means of treating pathologies of the vasculature.
No takes yet. Share an insight, caveat, or question.
Kalea et al. (2009) conducted a review in Vascular disease. RAGE (receptor for AGEs) was evaluated. Circulating RAGE protein levels and RAGE polymorphisms may serve as useful clinical tools for predicting vascular disease risk and offer potential targets for therapeutic intervention.
Synapse has enriched 10 related papers. Consider them for comparative context: